Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
The approval was based on data from the phase 1/2 ZUMA-3 trial which evaluated Tecartus in 71 adults with relapsed or refractory B-cell precursor ALL.
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Researchers sought to determine whether initiating exercise during chemotherapy was superior to initiation after chemotherapy.
Patients with breast implants are at risk of developing squamous cell carcinoma and various types of lymphoma in the capsules around the implants.
A novel blood test can detect cancers that currently have no standard screening procedures, a study suggests.
Transgender patients with cancer may be less likely to receive adequate care and have worse outcomes than their cisgender counterparts.
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.